Test&Treat Ltd


The problem

UTIs are one of the most frequent clinical bacterial infections in women, accounting for nearly 25% of all infections and costing $6 billion globally.

50-60% of women will experience a UTI in their lifetime.

In many suspect UTI cases, antibiotics are prescribed before the bacteria is identified and the antibiotic susceptibility profile is known. Over-prescription of antibiotics is a leading cause of antimicrobial resistance.

The technology

Test & Treat have designed a ground-breaking new Point of Care test, U-treat, that allows the clinician to detect a urinary tract infection AND prescribe the appropriate antibiotic, within an hour.

The solution

Test & Treat have already demonstrated the efficacy of U-treat in a UK based study. In this study not only did we analyse our technology, we also assessed the effect on patient treatment outcomes had U-treat technology been available to practitioners:

  • 57% of patients going to their GP for UTI symptoms were treated empirically
  • 28% of those treated empirically did not actually have a UTI
  • 55% of those treated empirically received an inappropriate antibiotic
  • 93.6% of those treated empirically would have received the correct treatment, had U-treat technology been available
  • None of the patients without a UTI, but prescribed empirical antibiotics, would have been given antibiotic treatment had the U-treat technology been available
  • In 28% of cases where treatment was switched to a second antibiotic post laboratory results, U-Treat technology identified the correct antibiotic at the time of presentation
  • Only 68.3% of patients in this study received appropriate antibiotic treatment as opposed to 92.7% of patients had U-Treat technology been available.

Test & Treat are looking to license our innovative new technology in both the UK and US medical markets. We are NIHR funding approved and have partnered with a reputable UK university to further develop our product.

If you are interested in knowing more about Test & Treat or are interested in licensing our technology in the human market, please contact us.